Theranostics in the fight against cancer
April 26, 2022 07:39 ET
|
University of the Free state
Bloemfontein, April 26, 2022 (GLOBE NEWSWIRE) -- According to the World Health Organisation (WHO), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or...
Two New Studies to Explore Telix Assets in Breast Cancer Theranostics
August 17, 2021 21:26 ET
|
Telix Pharmaceuticals Limited
Breast cancer one of several important indication expansion opportunities for the Telix portfolioFirst patient dosed at Emory University (Atlanta, USA) in a Phase I study of TLX591-CDx for the staging...
Telix Progresses Novel Lung and Ovarian Cancer Theranostic APOMAB®
August 16, 2021 20:03 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and ADELAIDE, Australia, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces it has extended its previously...
Global Somatic Genetic Testing Market Report 2021: Market to Reach $16.79 Billion by 2030
March 29, 2021 05:08 ET
|
Research and Markets
Dublin, March 29, 2021 (GLOBE NEWSWIRE) -- The "Global Somatic Genetic Testing Market: Focus on Product Type, Sample, Technology, Applications, End Users, Country Data (15 Countries), and...
Global Genomics Partnering Terms and Agreements Analysis Report 2020
February 11, 2021 06:28 ET
|
Research and Markets
Dublin, Feb. 11, 2021 (GLOBE NEWSWIRE) -- The "Global Genomics Partnering Terms and Agreements 2014 to 2020" report has been added to ResearchAndMarkets.com's offering. The Global Genomics...
Global Theranostics Markets Report 2020: Oncology Segment Market for Theranostics Should Grow from $73.1 Billion in 2020 to $119.7 Billion by 2025
October 26, 2020 07:23 ET
|
Research and Markets
Dublin, Oct. 26, 2020 (GLOBE NEWSWIRE) -- The "Theranostics: Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for theranostics should grow from $80.4...
First Patient Dosed in Phase I/II Trial of Renal Cancer Imaging Product in Japan
August 17, 2020 20:00 ET
|
Telix Pharmaceuticals Limited
TOKYO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Japan K.K., a wholly-owned subsidiary of Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce that...
Telix Japan Signs MOU with ATOX to Use IRE ELiT 68Ge/68Ga-Generator for Phase I Study of Prostate Cancer Diagnostic Imaging
July 27, 2020 02:21 ET
|
Telix Pharmaceuticals Limited
TOKYO, July 27, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Japan K.K., a wholly-owned subsidiary of Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce it has...
Telix Pharmaceuticals Acquires Advanced Nuclear Medicine Ingredients (ANMI) SA
November 26, 2018 02:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, BRUSSELS and LIÈGE, Belgium, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company...